Showing 1811-1820 of 6037 results for "".
- Pharos Capital to Acquire Vantage Outsourcing, Build New Ophthalmology Services Platformhttps://modernod.com/news/pharos-capital-to-acquire-vantage-outsourcing-build-new-ophthalmology-services-platform/2480299/
- CEI Vision Partners Adds Virginia Eye Consultants as Fifth Partnerhttps://modernod.com/news/cei-vision-partners-adds-virginia-eye-consultants-as-fifth-partner/2476310/CEI Vision Partners (CVP), a portfolio company of Revelstoke Capital Partners LLC , a Denver-based private equity firm, has completed a partnership with Virginia Eye Consultants (VEC) , a premier multi-specialty ophthalmology group comprised of 17 providers that service the Norfolk, Virginia Beac
- Johnson & Johnson Vision Ceases Customer-Facing Operations for Sightbox Online Contact Lens Subscription Servicehttps://modernod.com/news/johnson-johnson-vision-ceases-customer-facing-operations-for-sightbox-online-contact-lens-subscription-service/2477054/
- Hovione Completes Phase 2 Clinical Trial of First Minocycline Ophthalmic for Dry Eye Disease Associated With Inflamed MGDhttps://modernod.com/news/hovione-completes-phase-2-clinical-trial-of-first-minocycline-ophthalmic-showing-promise-in-dry-eye-disease-associated-with-inflamed-mgd/2478986/Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its phase 2 clinical trial in 270 patients with dry eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 clinical sites in
- Nicox Appoints New Chair of the Board and Directorhttps://modernod.com/news/nicox-appoints-new-chair-of-the-board-and-director/2482357/Nicox announced the appointment of the experienced healthcare executive Damian Marron as Chair of the Board of Directors. Marc Le Bozec, an experienced life sciences entrepreneur, was appointed as a new Director of Nicox. Jean-François Labbe is retir
- Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-screened-in-the-whistler-phase-3b-trial-of-ncx-470-in-glaucoma/2482018/Nicox announced that the first patient has been screened in the Whistler phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in IOP lowering. NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, is the company's le
- Novavax’s COVID-19 Vaccine Over 89% Effective in UK trial, Less So in South Africa Studyhttps://modernod.com/news/novavaxs-covid-19-vaccine-over-89-effective-in-uk-trial-less-so-in-south-africa-study/2478809/Novavax shares gained as much as 26% on Thursday after the company said its protein-based COVID-19 vaccine candidate NVX-CoV2373 met the primary endpoint of a phase 3 trial in the UK, demonstrating an efficacy rate of over 89%, with high protection also seen against the fast-spreading UK variant.
- Ora Names Gustavo De Moraes, MD, PHD, Chief Medical Officerhttps://modernod.com/news/ora-names-gustavo-de-moraes-md-phd-chief-medical-officer/2480622/Ora announced that distinguished op
- Mount Sinai Recruits Internationally Recognized Ophthalmologists to Expand Leadershiphttps://modernod.com/news/mount-sinai-recruits-internationally-recognized-ophthalmologists-to-expand-leadership/2479609/Mount Sinai Health System announced the appointment of two new faculty members to expand leadership in the Department of Ophthalmology. Louis R. Pasquale, MD, FARVO, has been named Site Chair of Ophthalmology at The Mount Sinai Hospital and Mount Sinai Queens and will also serve as Vice Chair of
- SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Painhttps://modernod.com/news/siteone-therapeutics-receives-nih-grant-to-support-the-development-of-novel-therapeutics-to-treat-ocular-pain/2479849/SiteOne Therapeutics announced that the company has been awarded a $1.4 million, 2-year, phase 2 SBIR grant from the National Eye Institute (NEI), a member of the US National Institutes of Health (NIH). The award will be used to initiate IND-enabling studies for Site